CuraGen Presents Update on Clinical Development Program for
Belinostat
- Clinical activity reported against CTCL, PTCL and Ovarian Cancers- BRANFORD, Conn., June 12, 2007 /PRNewswire-FirstCall/ --
CuraGenCorporation , a clinical-stage biopharmaceutical company focused ononcology, presented today an update on the clinical developmentprogram for belinostat, a histone deacetylase (HDAC) inhibitor, andreported updated results suggesting clinical activity of beli...
CuraGen and TopoTarget Announce New Clinical Results With
Belinostat to be Reported at Upcoming Major Medical Meetings
BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ --
CuraGen Corporation and TopoTarget A/S announced today thatpreliminary interim clinical data on intravenous belinostat(PXD101), a histone deacetylase (HDAC) inhibitor being investigatedfor the treatment of cancer, are expected to be presented at twoupcoming major medical meetings. One oral and one poster presentation discussi...
CuraGen Announces New Preclinical Results with Belinostat and
Velafermin to be Presented at AACR Annual Meeting
BRANFORD, Conn., April 12, 2007 /PRNewswire-FirstCall/ --
CuraGen Corporation announced today that new preclinical data onbelinostat (PXD101), a histone deacetylase (HDAC) inhibitor beinginvestigated for the treatment of cancer, and velafermin, a proteinbeing investigated for the prevention of severe oral mucositis,will be presented at the upcoming American Association for CancerResearch...